ZA202304812B - Pharmaceutical composition for preventing or treating viral perivaginal disease - Google Patents
Pharmaceutical composition for preventing or treating viral perivaginal diseaseInfo
- Publication number
- ZA202304812B ZA202304812B ZA2023/04812A ZA202304812A ZA202304812B ZA 202304812 B ZA202304812 B ZA 202304812B ZA 2023/04812 A ZA2023/04812 A ZA 2023/04812A ZA 202304812 A ZA202304812 A ZA 202304812A ZA 202304812 B ZA202304812 B ZA 202304812B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical composition
- vaginal
- core particles
- preventing
- perivaginal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020180339 | 2020-10-28 | ||
| PCT/JP2021/006418 WO2022091442A1 (ja) | 2020-10-28 | 2021-02-19 | ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202304812B true ZA202304812B (en) | 2024-08-28 |
Family
ID=81382191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/04812A ZA202304812B (en) | 2020-10-28 | 2023-04-26 | Pharmaceutical composition for preventing or treating viral perivaginal disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230398107A1 (https=) |
| EP (1) | EP4238565B1 (https=) |
| JP (1) | JP7606239B2 (https=) |
| KR (1) | KR20230098175A (https=) |
| CN (1) | CN115734782A (https=) |
| CA (1) | CA3199945A1 (https=) |
| ES (1) | ES3045576T3 (https=) |
| PL (1) | PL4238565T3 (https=) |
| TW (1) | TWI890738B (https=) |
| WO (1) | WO2022091442A1 (https=) |
| ZA (1) | ZA202304812B (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63275519A (ja) * | 1987-05-06 | 1988-11-14 | Taisho Pharmaceut Co Ltd | 難溶性薬物含有顆粒の製造方法 |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| JP2007517062A (ja) | 2003-12-29 | 2007-06-28 | アルザ・コーポレーシヨン | 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング |
| JP5349309B2 (ja) * | 2007-08-03 | 2013-11-20 | 株式会社キノファーマ | 抗dnaウイルス作用を有するアニリン誘導体 |
| JP2010189337A (ja) * | 2009-02-19 | 2010-09-02 | Asahi Breweries Ltd | 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法 |
| JP6138635B2 (ja) * | 2013-08-30 | 2017-05-31 | 旭化成株式会社 | セルロース系核粒子及びその製造方法 |
| WO2020218518A1 (ja) * | 2019-04-25 | 2020-10-29 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
| WO2020218517A1 (ja) * | 2019-04-25 | 2020-10-29 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
-
2021
- 2021-02-19 US US18/033,584 patent/US20230398107A1/en active Pending
- 2021-02-19 KR KR1020237014225A patent/KR20230098175A/ko active Pending
- 2021-02-19 PL PL21885567.4T patent/PL4238565T3/pl unknown
- 2021-02-19 CA CA3199945A patent/CA3199945A1/en active Pending
- 2021-02-19 CN CN202180045812.6A patent/CN115734782A/zh active Pending
- 2021-02-19 WO PCT/JP2021/006418 patent/WO2022091442A1/ja not_active Ceased
- 2021-02-19 JP JP2022558836A patent/JP7606239B2/ja active Active
- 2021-02-19 EP EP21885567.4A patent/EP4238565B1/en active Active
- 2021-02-19 ES ES21885567T patent/ES3045576T3/es active Active
- 2021-02-19 TW TW110105759A patent/TWI890738B/zh active
-
2023
- 2023-04-26 ZA ZA2023/04812A patent/ZA202304812B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022091442A1 (ja) | 2022-05-05 |
| JP7606239B2 (ja) | 2024-12-25 |
| KR20230098175A (ko) | 2023-07-03 |
| EP4238565C0 (en) | 2025-09-24 |
| PL4238565T3 (pl) | 2025-12-22 |
| ES3045576T3 (en) | 2025-11-28 |
| EP4238565A4 (en) | 2024-10-09 |
| CA3199945A1 (en) | 2022-05-05 |
| EP4238565A1 (en) | 2023-09-06 |
| JPWO2022091442A1 (https=) | 2022-05-05 |
| EP4238565B1 (en) | 2025-09-24 |
| TW202216142A (zh) | 2022-05-01 |
| TWI890738B (zh) | 2025-07-21 |
| US20230398107A1 (en) | 2023-12-14 |
| CN115734782A (zh) | 2023-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013892A (es) | Analogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibicion de la helicasa recq del sindrome de werner (wrn). | |
| JP5860197B1 (ja) | ウイルス感染症を処置するための治療用化合物 | |
| KR101235102B1 (ko) | 플리반세린을 포함하는 성욕 장애 치료용 약제학적 조성물 | |
| MY202837A (en) | Lipids for lipid nanoparticle delivery of active agents | |
| TW202019900A (zh) | Ptpn11抑制劑 | |
| JP5192517B2 (ja) | 治療又は予防薬 | |
| HRP20100180T1 (hr) | Novi spoj piridazina i njegova primjena | |
| MXPA04000905A (es) | Derivados de amino-ftalazinona activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| CN102532133A (zh) | 适用作詹纳斯激酶抑制剂的吖吲哚类 | |
| EA200970535A1 (ru) | Антибактериальные производные хинолина | |
| RU2014105577A (ru) | Капсулированная лекарственная форма, содержащая монтелукаст и левоцетиризин | |
| US10945996B2 (en) | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | |
| AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
| WO2012058378A1 (en) | Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses | |
| JOP20180071B1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| CA2645211A1 (en) | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | |
| SI2800558T1 (en) | A stable pharmaceutical formulation for oral administration comprising levocetirizines or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| EA200970534A1 (ru) | Антибактериальные производные хинолина | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| ZA202304812B (en) | Pharmaceutical composition for preventing or treating viral perivaginal disease | |
| MX2023001725A (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos. | |
| BR0210191A (pt) | Agentes não peptìdicos da gnrh, composições farmacêuticas e métodos para o seu uso, e processos para os preparar e aos seus intermediários | |
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| ZA202108670B (en) | Pharmaceutical preparation and method for producing same | |
| US20080161249A1 (en) | Use of Novel Antibacterial Compounds |